Specialty Pharmacy

Epoetin alfa biosimilar shows promise in early study.

Pollutants may accelerate fibrosis, metabolic disease, and liver cancer.

Treatment with bevacizumab and lomustine not found to offer a survival advantage.

Top recent news in cancer drug development.

NS3 enzyme interacts with RNA and helps the pathogen replication process.

Chemosensitivity, treatment variations, and socioeconomic factors may be a significant factor.

Excess production of tumor necrosis factor causes both RA and the onset of heart valve disease.

Depression and smoking status may be valuable targets for interventions from care providers.

Engineered antibody treatment imitates functioning factor VIII to make blood clot properly.

Psychosis and hepatic fibrosis associated with earlier mortality.

Processed and red meat products like bacon and salami previously deemed carcinogenic to humans.

Legislators focus on the pricing of sofosbuvir and Harvoni.

Janssen is seeking FDA approval for ustekinumab as a Crohn's disease treatment.

A measure to delay the unpopular "Cadillac tax," part of President Obama's health reform law, overwhelmingly passed the Senate by a 90-10 vote on Thursday.

The World Health Organization indicates that 35 million individuals have HIV worldwide, and 4 to 5 million HIV-infected patients are co-infected with hepatitis C virus.

FDA decision expected in second half of 2016.

Study finds potential link between HCV treatment and drug-induced hepatotoxicity.

Balanced approach needed to better discriminate between high and low disease activity.

Micronutrient deficiencies in patients with HIV causes high prevalence of anemia and inflammation.

Targets for savings needed to cover retirees' health care expenses are rising.

Researchers confirm antidepressants do not cause recurrence in breast cancer patients treated with tamoxifen.

Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.

Hepatitis C infection causes more deaths than HIV, hepatitis B, and tuberculosis combined.

UnitedHealth is the only company to announce it may depart from insurance exchanges.

The $750 per pill price of pyrimethamine could soon be undercut by a new compound selling for $1 per pill.

Pharmacy leaflets hold much potential for helping patients properly assess the risks and benefits of their medications.

Research finds patients are not staying on methotrexate long enough before switching to more costly biologic drugs.

Catch up with any news you missed last month.